Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.57 |
| ▸ | QDPR | P09417 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698265 | 0.90 | HTR2A (0.53) | HTR2CHTR2ASLC6A2SLC6A4HTR3A | |
| SCHEMBL28294833 | 0.88 | KDM1A (0.43) | HTR2CHTR2AADRA2ACHRNB2ADRA2C | |
| SCHEMBL18161909 | 0.88 | KDM1A (0.43) | HTR2CHTR2AADRA2ACHRNB2ADRA2C | |
| SCHEMBL5537443 | 0.87 | HTR2C (0.57) | HTR2CQDPRSLC18A3SIGMAR1HTR2A | |
| SCHEMBL3719147 | 0.86 | HTR2C (0.61) | HTR2CQDPRSLC18A3SIGMAR1HTR2A | |
| Hydrochloric Acid SCHEMBL4893701 | 0.85 | HTR2C (0.58) | HTR2CQDPRSLC18A3SIGMAR1HTR2A | |
| SCHEMBL17102301 | 0.82 | HTR2C (0.56) | HTR2CQDPRSLC18A3SIGMAR1HTR2A | |
| SCHEMBL31342813 | 0.82 | HTR2C (0.56) | HTR2CQDPRSLC18A3SIGMAR1HTR2A | |
| SCHEMBL2710169 | 0.82 | HTR2C (0.56) | HTR2CQDPRSLC18A3SIGMAR1HTR2A | |
| SCHEMBL30228726 | 0.82 | HTR2C (0.56) | HTR2CQDPRSLC18A3SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104024251-B | Benzenesulfonamide compounds and their use as therapeutic agents | 克赛农制药股份有限公司 | 2017-08-11 | — | — | CN | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | HTR2C 67/4885QDPR 557/4885SLC18A3 233/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | HTR2C 67/4885QDPR 557/4885SLC18A3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.